USF-LVHN SELECT
Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration.
Publication/Presentation Date
1-1-2023
Abstract
Age-related macular degeneration (AMD) is characterized as a chronic, multifactorial disease and is the leading cause of irreversible blindness. Advanced AMD is classified as neovascular (wet) AMD and non-neovascular (dry) AMD. Dry AMD can progress to a more advanced form that manifests as geographic atrophy (GA), which significantly threatens vision, leading to progressive and irreversible loss of visual function. There are currently no approved therapeutics commercially available for GA patients. However, data from various clinical trials have demonstrated favorable results with significant reduction in GA lesion growth. This review furthers the understanding of the pathophysiology of GA, as well as current clinical trial data on investigational therapeutics.
Volume
17
First Page
321
Last Page
327
ISSN
1177-5467
Published In/Presented At
Khan, H., Aziz, A. A., Sulahria, H., Khan, H., Ahmed, A., Choudhry, N., Narayanan, R., Danzig, C., & Khanani, A. M. (2023). Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration. Clinical ophthalmology (Auckland, N.Z.), 17, 321–327. https://doi.org/10.2147/OPTH.S367089
Disciplines
Medical Education | Medicine and Health Sciences
PubMedID
36741078
Department(s)
USF-LVHN SELECT Program, USF-LVHN SELECT Program Students
Document Type
Article